Salud financiera de hoja de balance de Ionis Pharmaceuticals
Salud financiera controles de criterios 4/6
Ionis Pharmaceuticals tiene un patrimonio de los accionistas total de $386.7M y una deuda total de $1.8B, lo que sitúa su ratio deuda-patrimonio en 462.5%. Sus activos y pasivos totales son $3.0B y $2.6B respectivamente.
Información clave
462.5%
Ratio deuda-patrimonio
US$1.79b
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$2.34b |
| Patrimonio | US$386.69m |
| Total pasivo | US$2.60b |
| Activos totales | US$2.99b |
Actualizaciones recientes sobre salud financiera
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
Aug 08Recent updates
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Apr 14Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Nov 16Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Ionis: 2 Drug Advancements With Potential Firsts
Aug 29Ionis Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
Aug 08Ionis Pharma: Too Many Programs Have Failed To Produce Confidence
Jun 15Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
Apr 06Ionis Pharmaceuticals: Finding Financial Value In Biotech Research
Mar 27Ionis: At A Show-Me Crossroads
Mar 14Some Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates
Feb 25Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 28Ionis Has A Lot Of Upside, I Am Bullish On This Stock
Dec 16Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($2.6B) de IONS superan a sus pasivos a corto plazo ($448.1M).
Pasivo a largo plazo: Los activos a corto plazo de IONS ($2.6B) superan a sus pasivos a largo plazo ($2.2B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: IONS tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de IONS ha crecido de 54% a 462.5% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: IONS tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si IONS tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.